Skip to content

Evaluation of the effect of Dihydroartemisinin on early type 2 diabetes: a preliminary clinical feasibility study.

Evaluation of the effect of Dihydroartemisinin on early type 2 diabetes: a preliminary clinical feasibility study.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-17010789
Enrollment
Unknown
Registered
2017-03-05
Start date
2017-03-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

Treatment group: Dihydroartemisinin
Control:Placebo

Sponsors

The First Affiliated Hospital of Henan University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-60 years; BMI = 25Kg/ square meters; 2. For the first time found that elevated blood sugar (according to diabetes diagnostic criteria of WHO in 1999); 3. Glycosylated hemoglobin is less than or equal to 8%; 4. No ketosis; 5. Voluntary testing and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Does not meet the inclusion criteria; 2. Concomitant with other acute and chronic diseases (being treated with drugs) or other metabolic diseases; 3. Pregnancy, pre-term(within 6 months) pregnancy , breast-feeding women; 4. Use of immunosuppressants in the last month; 5. Drug intolerance; 6. Other circumstances not included in the study.

Design outcomes

Primary

MeasureTime frame
Glycosylated Hemoglobin;Fasting blood glucose;Lipid profile;;

Secondary

MeasureTime frame
weight;

Countries

China

Contacts

Public ContactHongwei Jang

The First Affiliated Hospital of Henan University of Science and Technology

jhwdr6@163.com+86 13653880139

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026